title: Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing's syndrome in a medullary thyroid carcinoma patient.
abstract: A 55-year-old woman diagnosed with sporadic MTC underwent total thyroidectomy 20 years ago. After the first surgery, elevated calcitonin levels in parallel with local disease persistence were noted and therefore she underwent repeated neck dissections. During follow-up, multiple foci of metastatic disease were noted in the neck and mediastinal lymph nodes, lungs and bones; however, the disease had an indolent course for a number of years, in parallel with a calcitonin doubling time of more than two years and without significant symptoms. During a routine follow-up visit 2 years ago, findings suggestive of Cushing's syndrome were observed on physical examination. The biochemical evaluation demonstrated markedly elevated serum calcitonin level, in parallel with lack of cortisol suppression after an overnight 1 mg dexamethasone suppression test, lack of cortisol and ACTH suppression after high-dose IV dexamethasone 8 mg, elevated plasma ACTH up to 79 pg/mL (normal <46 pg/mL) and elevated 24-h urinary free cortisol up to 501 µg/24 h (normal 9-90 µg/24 h). After a negative pituitary MRI, she underwent IPSS, which was compatible with EAS. Whole-body CT demonstrated progressive disease at most of the tumor sites. Treatment with vandetanib at a dosage of 200 mg/day was commenced. The patient showed a significant, rapid and consistent clinical improvement already after two months of treatment, in parallel with biochemical improvement, whereas a decrease in tumor size was demonstrated on follow-up CT.
  
  
  CONCLUSIONS
  Ectopic Cushing's syndrome due to ectopic ACTH secretion (EAS) by MTC is an uncommon and a poor prognostic event, being associated with significant morbidity and mortality.We demonstrate that vandetanib is effective in controlling the signs and symptoms related to the EAS in patients with advanced progressive MTC.We demonstrate that vandetanib is effective in decreasing tumor size and in inducing tumor control.
authors.affiliation: Department of Medicine , Neuroendocrine Tumor Unit, Endocrinology & Metabolism Service.
authors.forename: Hashem
authors.initials: H
authors.lastname: Bseiso
authors.affiliation: Department of Radiology , Hadassah-Hebrew University Medical Center, Jerusalem , Israel.
authors.forename: Naama
authors.initials: N
authors.lastname: Lev-Cohain
authors.affiliation: Department of Medicine , Neuroendocrine Tumor Unit, Endocrinology & Metabolism Service.
authors.forename: David J
authors.initials: DJ
authors.lastname: Gross
authors.affiliation: Department of Medicine , Neuroendocrine Tumor Unit, Endocrinology & Metabolism Service.
authors.forename: Simona
authors.initials: S
authors.lastname: Grozinsky-Glasberg